Guangzhou Innogen Pharmaceutical Group Co Ltd

Guangzhou Innogen Pharmaceutical Group Co Ltd has a market capitalization of 5.46 billion CNY, with a market price of 11.96 CNY per share. The company has 456.82 million shares outstanding, with no dilution observed between basic and diluted shares. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents.

The company's profitability and returns are not yet quantified against industry benchmarks, as no specific metrics such as ROIC, EBITDA margins, or net profit margins are available in the valuation snapshot. Analysts have assigned a mean price target of 31.35 CNY, with a median of 31.35 CNY, indicating a potential upside of 162.11% from the current market price.

Segment and geographic exposure data are not disclosed in the available financial snapshot, making it difficult to assess revenue concentration or geographic diversification. The company's business is likely concentrated in China, given its listing on the Hong Kong Stock Exchange and the absence of international revenue breakdowns.

Growth trajectory is not explicitly outlined in the available data, but the significant analyst price target suggests optimism about future performance. No specific revenue history or outlook for the current or next fiscal year is provided in the input data.

Risk factors include the inability to assess liquidity risk and the lack of detailed balance-sheet inputs. The company is also exposed to the broader pharmaceutical industry's regulatory and competitive pressures, though no specific geopolitical drivers are cited in the input data.

Recent events, such as filings or transcripts, are not included in the input data, so no specific developments can be cited at this time.

Revenue ¥131.5M; Operating income −95,4% YoY.

• ▍Revenue ¥131.5M
• ▍Operating income −95,4% YoY
• ▍Net income −95,4% YoY
• ▍Free cash flow −118,0% YoY
• ▍Net margin -259.6%